Latest Panitumumab Stories
Data presented at the EORTC-NCI-AACR International Symposium Demonstrate High Sensitivity and Strong Quantitative Performance with Trovagene's Precision Cancer Monitoring Platform BARCELONA,
Introduction of Extended RAS Testing and Recent Clinical Trial Data Will Affect How Physicians Treat Colorectal Cancer Patients, According to Findings from Decision Resources Group BURLINGTON,
For patients with KRAS wild-type untreated colorectal cancer, adding cetuximab or bevacizumab to combination chemotherapy offers equivalent survival.
Study Shows Improved Survival Benefit in Panitumumab Arm THOUSAND OAKS, Calif., May 31, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from the Phase 2 PEAK study that reinforce
New Data Reinforces Commitment to Personalized Medicine and Highlights Advances in Immunotherapy Platform THOUSAND OAKS, Calif.
GERMANTOWN, Maryland and HILDEN, Germany, May 23, 2014 /PRNewswire/ -- - Clinically proven companion diagnostic gains U.S.
Vectibix is the First and Only Biologic to Offer Significant Survival Benefit as a First-Line Treatment with FOLFOX Chemotherapy for Patients with Wild-Type KRAS Metastatic Colorectal Cancer THOUSAND
LONDON, April 3, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:
Introducing CE-IVD marked kits with expanded mutation coverage in colorectal cancer for Kras, Nras, and Braf genes. Tarzana, Calif (PRWEB) January 29, 2014
Science philanthropist, Jeffrey Epstein and the founder of the Program for Evolutionary Dynamics at Harvard University has helped fund pivotal research in how to combat colon cancer and specifically
- A member of the swell-mob; a genteelly clad pickpocket. Sometimes mobsman.